Home > Formulary : Adult > Chapters > 3. Respiratory System >
BNSSG Adult Joint Formulary
3.5 Interstitial Lung Disease
Last edited: 19-06-2024
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
Antifibrotics
Pirfenidone (TLS Red)
Commissioned by NHS England Specialised Services Commissioning via Prior Approval Scheme on Blueteq
- NICE TA504 Pirfenidone - treatment of idiopathic pulmonary fibrosis
Nintedanib (TLS Red)
Commissioned by NHS England Specialised Services Commissioning via Prior Approval Scheme on Blueteq
- NICE TA379 Nintedanib for treating idiopathic pulmonary fibrosis
- NICE TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases
- NICE TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Azathioprine (TLS Amber 1 month) (SCP Click here)
Methotrexate (TLS Amber 1 month) (SCP Click here)
- When used for sarcoidosis
Mycophenolate (TLS Amber 3 months) (SCP Click here)
- When used for immunomodulation / immunosuppression (unlicensed) under specialist supervision
Contact Us
Got a question or comment about the Joint Formulary?
Please use the email address below to contact us and we will endeavour to respond within 2 working days.